Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study

Purpose: Adjuvant treatment decisions in early breast cancer (eBC) have traditionally been driven by risk stratification based on clinical and pathological risk factors. The 21-gene Oncotype DX® assay has been validated as a predictive test for benefit from adjuvant chemotherapy (CT), hence assessin...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Alberto Zambelli, Edda Simoncini, Monica Giordano, Nicla La Verde, Gabriella Farina, Valter Torri, Giorgio Colombo, Giulia Piacentini, Vittoria Fotia, Lucia Vassalli, Palma Pugliese, Paola Poletti, Elena Rota Caremoli, Carlo Tondini
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2020-08-01
Saila:	Breast
Gaiak:	Decision impact Early breast cancer 21-gene assay Oncotype DX Recurrence Score Adjuvant chemotherapy
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S0960977620300904
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!